Trial Profile
A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 19 Jan 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.